A5004617633- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- Advanced Breast Cancer Therapies
- BRCA gene mutations in cancer
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Gene expression and cancer classification
- Cancer Cells and Metastasis
- Breast Lesions and Carcinomas
- Global Cancer Incidence and Screening
- Genetic factors in colorectal cancer
- Cancer Risks and Factors
- Radiomics and Machine Learning in Medical Imaging
- Bioinformatics and Genomic Networks
- Cancer-related Molecular Pathways
- Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Nutrition, Genetics, and Disease
- Molecular Biology Techniques and Applications
- Cancer, Hypoxia, and Metabolism
- Respiratory Support and Mechanisms
- Ferroptosis and cancer prognosis
- Angiogenesis and VEGF in Cancer
Karolinska Institutet
2015-2024
Karolinska University Hospital
2012-2024
University of Helsinki
2008-2021
Genome Institute of Singapore
2018
University of California, San Francisco
2014-2017
Sahlgrenska University Hospital
1985-2017
Virginia Commonwealth University
2017
Skåne University Hospital
2017
UNC Lineberger Comprehensive Cancer Center
2017
Linköping University
2016-2017
PURPOSE To investigate whether hormonal receptors and human epidermal growth factor receptor 2 (HER2) change throughout tumor progression, because this may alter patient management. PATIENTS AND METHODS The study cohort included female patients with breast cancer in the Stockholm health care region who relapsed from January 1, 1997, to December 31, 2007. Either biochemical or immunohistochemical (IHC)/immunocytochemical (ICC) methods were used determine estrogen (ER), progesterone (PR), HER2...
Whether young age at diagnosis of breast cancer is an independent risk factor for death remains controversial, and the question whether should be considered in treatment decisions still to answered. From a population-based cohort 22,017 women with cancer, all <35 years (n = 471) were compared random sample 700 aged 35–69 from same cohort. Information on patient tumor characteristics, treatment, follow-up was collected medical records. Tissue microarrays produced analysis classical...
The frequency of cancers with indolent behavior has increased screening. Better tools to identify tumors are needed avoid overtreatment.To determine if a multigene classifier is associated invasive breast in women followed for 2 decades.This secondary analysis randomized clinical trial tamoxifen vs no systemic therapy, more than 20-year follow-up. An threshold (ultralow risk) the US Food and Drug Administration-cleared MammaPrint 70-gene expression score was established above which cancer...
Vascular and bleeding complications increase morbidity mortality in transcatheter aortic valve replacement (TAVR). However, data regarding the efficacy safety of MANTA percutaneous vascular closure device (VCD) are scarce. The present study sought to compare VARC-2 between collagen plug-based using "MANTA" suture-based "ProGlide" evaluate novel VCD.We performed a retrospective, propensity score-matched 325 consecutive patients who underwent TAVR ProGlide. 1:1 score matching resulted 111...
Power spectrum analysis of the diaphragm electromyogram (EMGdi) is time consuming, and no criteria have been developed to objectively quantify contamination signal. The present work describes a set computer algorithms that automatically select EMGdi free electrocardiogram numerically common artifacts affect EMGdi. were tested 1) on human (n = 5) obtained with esophageal electrodes positioned at level gastroesophageal junction, 2) in mongrel dogs intramuscular costal diaphragm, 3)...
We and others have recently shown that tumor characteristics are altered throughout progression. These findings emphasize the need for re-examination of at relapse led to recommendations from ESMO Swedish Breast Cancer group. Here, we aim determine whether molecular subtypes in breast cancer metastases confer clinically relevant prognostic information patients.
Summary Background Patients with primary sclerosing cholangitis ( PSC ) and inflammatory bowel disease IBD have a high risk of developing colorectal cancer dysplasia. Ursodeoxycholic acid UDCA has been suggested to chemopreventive effects on the development dysplasia but long‐term data larger trials are lacking. Aim To evaluate effect dose (17–23 mg/kg/day) neoplasia in cohort patients . Methods From our previous 5‐year randomised controlled trial vs. placebo , we performed follow‐up 98...
Breast cancer patients with estrogen receptor (ER)–positive disease have a continuous long-term risk for fatal breast cancer, but the biological factors influencing this are unknown. We aimed to determine whether high intratumor heterogeneity of ER predicts an increased (25 years) cancer. The STO-3 trial enrolled 1780 postmenopausal lymph node–negative randomly assigned receive adjuvant tamoxifen vs not. fraction cells each intensity level was scored by pathologists, and calculated using...
Use of cyclin D1 (CCND1) gene amplification as a breast cancer biomarker has been hampered by conflicting assessments the relationship between protein levels and patient survival. Here, we aimed to clarify its prognostic treatment predictive potential through comprehensive long-term survival analyses. CCND1 was assessed using SNP arrays from two cohorts 1965 340 patients with matching expression array clinical follow-up data over 15 years. Kaplan-Meier multivariable Cox regression analyses...
<h3>Importance</h3> Benign breast diseases (BBDs) are common and associated with cancer risk, yet the etiology risk of BBDs have not been extensively studied. <h3>Objective</h3> To investigate by age, hormonal factors, family history cancer. <h3>Design, Setting, Participants</h3> This retrospective cohort study assessed 70 877 women from population-based Karolinska Mammography Project for Risk Prediction Breast Cancer (KARMA) who attended mammographic screening or underwent clinical...
Mutational inactivation of the FBXW7/hCDC4 tumor suppressor gene (TSG) is common in many cancer types, but infrequent breast cancers. This study investigates presence and impact promoter methylation cancer.FBXW7/hCDC4-β expression was assessed 161 tumors from two independent cohorts. Associations between status clinicopathologic characteristics were by Fisher's exact test. Survival analyzed using Kaplan-Meier method addition to modeling risk use a multivariate proportional hazard (Cox) model...
Exploration of new strategies for the prevention breast cancer metastasis is justifiably at center clinical attention. In this study, we combined a computational biology approach with mechanism-based preclinical trials to identify inhibitors activin-like receptor kinase (ALK) 1 as effective agents blocking angiogenesis and in cancer. Pharmacologic targeting ALK1 provided long-term therapeutic benefit mouse models mammary carcinoma, accompanied by strikingly reduced metastatic colonization...
Gene signatures and Ki67 stratify the same breast tumor into opposing good/poor prognosis groups in approximately 20% of patients. Given this discrepancy, we hypothesized that combination a clinically relevant signature IHC markers may provide more prognostic information than either classifier alone.
Breast tumors have traditionally been categorized into four widely recognized subtypes. Recent single-cell advancements however shown that individual can contain more than one subtype, exhibiting their intrinsic heterogeneity. Relatedly, whilst the crucial role of cell cycle regulation in cancer development is acknowledged, specific impact phases on oncogenic signaling and processes each these subtypes remains unresolved. Here, we examine differences transcriptomic hallmarks across within...
Patients with estrogen receptor (ER)-positive breast cancer have a long-term risk for fatal disease. However, the tumor biological factors that influence and benefit associated endocrine therapy are not well understood.To compare survival from tamoxifen patients luminal A or B subtype.Secondary analysis of Stockholm Tamoxifen (STO-3) trial conducted 1976 to 1990, which randomized postmenopausal lymph node-negative receive adjuvant no therapy. Tumor tissue sections were assessed in 2014 using...
PURPOSE To assess the long-term (20-year) endocrine therapy benefit in premenopausal patients with breast cancer. METHODS Secondary analysis of Stockholm trial (STO-5, 1990-1997) randomly assigning 924 to 2 years goserelin (3.6 mg subcutaneously once every 28 days), tamoxifen (40 orally daily), combined and tamoxifen, or no adjuvant (control) is performed. Random assignment was stratified by lymph node status; node–positive (n = 459) were allocated standard chemotherapy (cyclophosphamide,...
A genetic component is well established in the etiology of breast cancer. It not known, however, whether traits also influence prognostic features malignant phenotype.We carried out a population-based cohort study Sweden based on nationwide Multi-Generation Register. Among all women with cancer diagnosed from 1961 to 2001, 2,787 mother-daughter pairs and 831 sister were identified; we achieved complete follow-up classified 5-year cancer-specific prognosis among proband (mother or oldest...
// Siker Kimbung 1, 2 , Anikó Kovács 3 Anna Danielsson 4 Pär-Ola Bendahl 1 Kristina Lövgren Marianne Frostvik Stolt 5 Nicholas P. Tobin Linda Lindström 6, 7 Jonas Bergh Zakaria Einbeigi Mårten Fernö Thomas Hatschek Ingrid Hedenfalk Division of Oncology and Pathology, Department Clinical Sciences, Lund University, Lund, Sweden CREATE Health Strategic Center for Translational Cancer Research, Pathology Cytology, Sahlgrenska University Hospital, Gothenburg, Oncology, Institute Academy,...
To understand which breast cancer (BC) risk factors also increase the of fibroadenoma and investigate whether these have same effect in BC patients with previous fibroadenoma.Using multistate survival analysis on a large dataset (n = 58 322), we examined effects transitions between three states: event-free, biopsy-confirmed fibroadenoma, BC. Hazard ratios corresponding 95% confidence intervals associated covariate were estimated. Median follow-up time was 25.3 years.The mean ages at...